Clinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy

Basit Öğe Kaydı
dc.authoridGörkem Türkkan / 0000-0002-9084-2599en_US
dc.authoridMerdan Fayda / 0000-0002-2800-5327
dc.authorscopusidGörkem Türkkan / 56841633300en_US
dc.authorscopusidMerdan Fayda / 6506348846
dc.authorwosidGörkem Türkkan / E-7048-2017en_US
dc.authorwosidMerdan Fayda / AAF-7370-2019en_US
dc.contributor.authorTürkkan, Görkem
dc.contributor.authorBilici, Nazlı
dc.contributor.authorSertel, Hüseyin
dc.contributor.authorKeşküş, Yavuz
dc.contributor.authorAlkaya, Sercan
dc.contributor.authorÖzkırım, Müge
dc.contributor.authorFayda, Merdan
dc.date.accessioned2022-09-06T10:47:04Z
dc.date.available2022-09-06T10:47:04Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractPurpose: To report our initial experience with 1.5 T magnetic resonance imaging (MRI) linear accelerator (LINAC) in prostate cancer radiotherapy in terms of its use in a radiation oncology clinic. Methods: The medical records of 14 prostate cancer patients treated with MRI-guided radiotherapy were retrospectively evaluated. The fraction time, adapt-to-position (ATP):adapt-to-shape (ATS) usage rate, machine-associated treatment interruption rate, median gamma pass rate, the percentage of planning target volume receiving at least 95% of the prescription dose coverage value of each ATS fraction, the effect of the learning curve on the fraction time and radiation-related acute gastrointestinal and genitourinary toxicities were evaluated. Results: Fourteen patients have completed their treatment receiving a total of 375 fractions. Six patients (42%) were treated with the moderately hypofractionated regimen, five patients (36%) with conventionally fractionated, and three patients (22%) with the ultra-hypofractionated radiotherapy regimens. The ATP : ATS usage ratio was 3:372. The median fraction time was 46 min (range, 24-81 min). For the 3%/3 mm criterion, median gamma pass rate was 99.4% (range, 94.6-100%). Machine-related treatment interruptions were observed in 11 (2.9%) of 375 fractions, but this interruption rate decreased from 4.1% to 0.8%, after an upgrade. Three patients (22%) had gastrointestinal and five patients (36%) had genitourinary toxicity. No ?grade 3 toxicity was observed. Conclusion: 1.5 T MRI-LINAC device could be used as a conventional LINAC device, when the conditions of the radiotherapy center are appropriate. MRI-guided prostate radiotherapy is safe and feasible, and high-quality studies with a larger number of patients and long-term results are needed to better evaluate this new technology.en_US
dc.identifier.citationTurkkan G, Bilici N, Sertel H, Keskus Y, Alkaya S, Tavli B, Ozkirim M, Fayda M. Clinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapy. Front Oncol. 2022 Aug 16;12:909402. doi: 10.3389/fonc.2022.909402. PMID: 36052268; PMCID: PMC9424496.en_US
dc.identifier.doi10.3389/fonc.2022.909402en_US
dc.identifier.issn2234-943Xen_US
dc.identifier.issue12en_US
dc.identifier.pmid9424496en_US
dc.identifier.scopus2-s2.0-85137057116en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttp://doi.org/10.3389/fonc.2022.909402
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3122
dc.identifier.volume16en_US
dc.identifier.wosWOS:000847326500001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorTürkkan, Görkem
dc.institutionauthorFayda, Merdan
dc.language.isoenen_US
dc.publisherPMCen_US
dc.relation.ispartofFrontiers in Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMRI-LINACen_US
dc.subjectMRI-Guided Radiotherapyen_US
dc.subjectAdaptive Radiotherapyen_US
dc.subjectFractionated Radiotherapyen_US
dc.subjectProstate Canceren_US
dc.titleClinical utility of a 1.5 T magnetic resonance imaging-guided linear accelerator during conventionally fractionated and hypofractionated prostate cancer radiotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
fonc-12-909402.pdf
Boyut:
1.2 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu